Compare INMB & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INMB | SBI |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 108.9M |
| IPO Year | 2018 | N/A |
| Metric | INMB | SBI |
|---|---|---|
| Price | $1.96 | $7.01 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | ★ 326.7K | 44.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.52% |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $7.11 |
| 52 Week High | $2.60 | $8.01 |
| Indicator | INMB | SBI |
|---|---|---|
| Relative Strength Index (RSI) | 40.57 | 18.11 |
| Support Level | $1.21 | N/A |
| Resistance Level | $2.17 | $7.89 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 0.00 | 0.00 |
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.